Artelon closed approximately $20 million in Series B funding. The financing will support commercial growth, clinical research and expansion of Artelon’s product line for the surgical treatment of ankles and other joints.
Artelon’s Dynamic Matrix technology is a proprietary polymeric bio-textile for musculoskeletal soft tissue reconstruction. Dynamic Matrix is designed to mimic the natural mechanical and biological properties of healing ligament tissue. It has demonstrated in clinical studies the ability to protect the surgical repair during early healing, quickly restore the mechanics of motion and support development of regenerating tissue before dissolving over five to six years.
“Artelon has focused deeply on surgical solutions for ankle instability, a large and underserved market,” said CEO Aaron Smith. “Ankle sprains are the number one reason for emergency room visits in the United States, and up to 20 percent of those patients will develop chronic instability after these injuries. While traditional surgical procedures can mitigate ankle instability, patients endure a long recovery period and can still have residual pain or instability over the long term.”
Artelon’s surgical solutions represent more than 30 years of research and expertise on the complex interaction of mechanics and biology in tendon and ligament reconstruction. “Following on the commercial success of our current Flexband SOLO and Flexband MULTI products, this funding will allow us to take on adjacent clinical indications and pursue leadership within the $2B U.S. ankle instability market, while expanding our efforts to address latent customer needs in other unstable joints.”
Artelon closed approximately $20 million in Series B funding. The financing will support commercial growth, clinical research and expansion of Artelon’s product line for the surgical treatment of ankles and other joints.
Artelon’s Dynamic Matrix technology is a proprietary polymeric bio-textile for musculoskeletal soft tissue reconstruction....
Artelon closed approximately $20 million in Series B funding. The financing will support commercial growth, clinical research and expansion of Artelon’s product line for the surgical treatment of ankles and other joints.
Artelon’s Dynamic Matrix technology is a proprietary polymeric bio-textile for musculoskeletal soft tissue reconstruction. Dynamic Matrix is designed to mimic the natural mechanical and biological properties of healing ligament tissue. It has demonstrated in clinical studies the ability to protect the surgical repair during early healing, quickly restore the mechanics of motion and support development of regenerating tissue before dissolving over five to six years.
“Artelon has focused deeply on surgical solutions for ankle instability, a large and underserved market,” said CEO Aaron Smith. “Ankle sprains are the number one reason for emergency room visits in the United States, and up to 20 percent of those patients will develop chronic instability after these injuries. While traditional surgical procedures can mitigate ankle instability, patients endure a long recovery period and can still have residual pain or instability over the long term.”
Artelon’s surgical solutions represent more than 30 years of research and expertise on the complex interaction of mechanics and biology in tendon and ligament reconstruction. “Following on the commercial success of our current Flexband SOLO and Flexband MULTI products, this funding will allow us to take on adjacent clinical indications and pursue leadership within the $2B U.S. ankle instability market, while expanding our efforts to address latent customer needs in other unstable joints.”
Copy to clipboard 
